Seattle brothers expand billion-dollar biotech company’s focus to include COVID

Published by
The Seattle Times

Harlan and Chad Robins started Seattle-based Adaptive Biotechnologies 12 years ago to find a cure for cancer. Now, they have broadened their mission to take on COVID-19. Adaptive sells an ultra-detailed blood test that analyzes immune responses to different diseases. It says the technology can advance research, diagnosis, and treatment of cancer, autoimmune disorders and infectious diseases. “Your immune system knows about every disease you have,” said Harlan Robins, chief scientific officer at Adaptive. “If we could just ask the immune system what it knows, we would be able to diagnose every …

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *